Q: Can A Single CDMO Manage Both Clinical And Commercial Biologics Supply?

Biologics development becomes more difficult when programs move from one vendor to another between clinical and commercial phases. Each transfer can introduce added coordination demands, knowledge gaps, technical risk, and regulatory complexity. Rezon Bio’s integrated model is designed to reduce those challenges by supporting clients from clinical GMP manufacturing through late-phase and commercial production with a single partner. Clinical-stage manufacturing at the Gdańsk facility is paired with FDA-approved late-phase and commercial capabilities at the Warsaw-Duchnice site, including up to two 2,000 L single-use bioreactors. Centralized program oversight also connects drug substance, drug product, formulation, quality, and project management activities.

For biotech teams approaching commercialization, this continuity can help protect process consistency, simplify communication, and create a smoother path from pivotal studies and PPQ to commercial supply.